Skip to main content
NTLA logo

NTLA

Intellia Therapeutics, Inc.

$13.04

1.96%

Trade Ideas Performance

Latest Closed Trade Idea

$13.04

1.96%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

6

Social

6

About

Events of Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock has been impacted by positive Phase 3 results from its HAELO trial for Lonvo-z, leading to a surge in the stock price. Following these results, Intellia initiated a rolling BLA submission to the FDA for Lonvo-z. The stock experienced a pullback due to a dilutive public offering of common stock. The FDA lifted clinical holds on Intellia's Nex-z trials for transthyretin amyloidosis. Earnings reports and analyst ratings have also influenced the stock.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Intellia Therapeutics, Inc. (NTLA) Live Stock Price, Chart & Financial News | Edge Hound